heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-20. Anything still debated is marked as such rather than presented as settled.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical for synthetic peptides |
| Solubility | Freely soluble in water | Also soluble in saline |
| Storage temperature | -20 C or below | Protect from repeated freeze-thaw |
| Analytical method | Reverse-phase HPLC | Confirms purity and identity |
| Common synonym | ACTH(4-10) analog | Reflects structural origin |
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Another application is in the military, where mobile pigment nanoparticles have been used to create more effective camouflage. Nanomaterials can also be used in three-way-catalyst applications, which have the advantage of controlling the emission of nitrogen oxides (NOx), which are precursors to acid rain and smog. In core-shell structure, nanomaterials form shell as the catalyst support to protect the noble metals such as palladium and rhodium. The primary function is that the supports can be used for carrying catalysts active components, making them highly dispersed, reducing the use of noble metals, enhancing catalysts activity, and potentially improving the stability.
Abortive initiation, the unproductive cycling of RNA polymerase before the promoter escape transition, results in short RNA fragments of around 9 bp in a process known as abortive transcription. The extent of abortive initiation depends on the presence of transcription factors and the strength of the promoter contacts.
Colistin, also known as polymyxin E, is an antibiotic medication used as a last-resort treatment for multidrug-resistant Gram-negative infections including pneumonia. These may involve bacteria such as Pseudomonas aeruginosa, carbapenem-resistant Klebsiella pneumoniae (CRKP), or Acinetobacter. It comes in two forms: colistimethate sodium can be injected into a vein, injected into a muscle, or inhaled, and colistin sulfate is mainly applied to the skin or taken by mouth. Colistimethate sodium is a prodrug; it is produced by the reaction of colistin with formaldehyde and sodium bisulfite, which leads to the addition of a sulfomethyl group to the primary amines of colistin. Colistimethate sodium is less toxic than colistin when administered parenterally. In aqueous solutions, it undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives, as well as colistin. Resistance to colistin began to appear as of 2015. Common side effects of the injectable form include kidney problems and neurological problems. Other serious side effects may include anaphylaxis, muscle weakness, and Clostridioides difficile-associated diarrhea. The inhaled form may result in constriction of the bronchioles. It is unclear if use during pregnancy is safe for the fetus. Colistin is in the polymyxin class of medications. It works by breaking down the cytoplasmic membrane, which generally results in bacterial cell death. Colistin was discovered in 1947 and colistimethate sodium was approved for medical use in the United States in 1970.
In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own. In 2019, the FDA rejected a Serepta Duchenne muscular dystrophy drug before reversing course 3 months later. The company opened a new Genetic Therapies Center of Excellence in Columbus, Ohio in October, 2021 in order to dramatically advance research into therapeutics for several muscular dystrophies that had begun at Nationwide Children's Hospital several years earlier. As of 2022, there are three FDA-approved DMD drugs in Sarepta Therapeutics' portfolio. In January 2023, Sarepta partnered with Catalent to manufacture delandistrogene moxeparvovec (SRP-9001). In June 2023, the FDA approved Sarepta Therapeutics’ fourth therapy, delandistrogene moxeparvovec-rokl, the first gene therapy to treat Duchenne muscular dystrophy (DMD). The product was approved under the accelerated approval pathway for 4-5 year olds with a confirmed DMD diagnosis. Accelerated approval requires that the product be studied further to verify its clinical benefit. In July 2025, Sarepta announced plans to lay off 500 employees, about 36% of its workforce, following the deaths of two patients linked to its Duchenne muscular dystrophy gene therapy, ELEVIDYS.
Sources: en.wikipedia.org
1993/3253) Customs Duties (ECSC) (Quota and other Reliefs) Order 1993 (S.I. 1993/3254) Medicines (Products Other Than Veterinary Drugs) (Prescription Only) Amendment (No. 2) Order 1993 (S.I. 1993/3256) Tribunals and Inquiries (Friendly Societies) Order 1993 (S.I. 1993/3258) Cardiff—Glan Conwy Trunk Road (A470) (Pentrebach—Cefn Coed Diversion) Order 1993 (S.I. 1993/3259) London Borough of Hackney (Lea Bridge-Cycle/Footbridge) Scheme 1993 Confirmation Instrument 1993 (S.I. 1993/3260) M42 Motorway (Junction 6 Southbound Off-Slip Road to Eastway) Scheme 1993 (S.I. 1993/3261) Export of Goods (Control) (Amendment No. 6) Order 1993 (S.I. 1993/3264) County Court (Amendment No. 4) Rules 1993 (S.I. 1993/3273) Land Registration Rules 1993 (S.I. 1993/3275) Land Registration (Official Searches) Rules 1993 (S.I. 1993/3276)
== Early life and education == Kendall was born in South Norwalk, Connecticut in 1886. He attended Columbia University, earning a Bachelor of Science degree in 1908, a Master of Science degree in Chemistry in 1909, and a Ph.D. in Chemistry in 1910.
In microorganisms and plants, the enzyme serine acetyltransferase catalyzes the transfer of acetyl group from acetyl-CoA onto L-serine to yield O-acetyl-L-serine. The following reaction step, catalyzed by the enzyme O-acetyl serine (thiol) lyase, replaces the acetyl group of O-acetyl-L-serine with sulfide to yield cysteine.
Sources: en.wikipedia.org
It was his 218th career home run, making his streak the then-longest among active players without a grand slam. Bagwell finished the 1998 season batting .304 with 34 home runs, 111 RBI, 124 runs scored, 19 stolen bases, 109 walks, .424 OBP, .557 SLG, .981 OPS. He ranked third in the league in runs scored and walks, fifth in OPS+, sixth in OBP, and eighth in OPS. The Astros won a franchise-best 102 games while winning the NL Central division title, leading the league in runs scored. Their season ended by defeat to the San Diego Padres in the NLDS, including losing two starts against Kevin Brown — both by a 2–1 score. Bagwell, Bell, and Biggio combined for six hits in 51 at bats in this series.
== Treatment == Myxomas are usually removed surgically. The surgeon removes the myxoma, along with at least 5 surrounding millimeters of atrial septum. The septum is then repaired, using material from the pericardium.
Radiocarbon dating is also simply called carbon-14 dating. Carbon-14 is a radioactive isotope of carbon, with a half-life of 5,730 years (which is very short compared with the above isotopes), and decays into nitrogen. In other radiometric dating methods, the heavy parent isotopes were produced by nucleosynthesis in supernovas, meaning that any parent isotope with a short half-life should be extinct by now. Carbon-14, though, is continuously created through collisions of neutrons generated by cosmic rays with nitrogen in the upper atmosphere and thus remains at a near-constant level on Earth. The carbon-14 ends up as a trace component in atmospheric carbon dioxide (CO2). A carbon-based life form acquires carbon during its lifetime. Plants acquire it through photosynthesis, and animals acquire it from consumption of plants and other animals. When an organism dies, it ceases to take in new carbon-14, and the existing isotope decays with a characteristic half-life (5730 years). The proportion of carbon-14 left when the remains of the organism are examined provides an indication of the time elapsed since its death. This makes carbon-14 an ideal dating method to date the age of bones or the remains of an organism. The carbon-14 dating limit lies around 58,000 to 62,000 years. The rate of creation of carbon-14 appears to be roughly constant, as cross-checks of carbon-14 dating with other dating methods show it gives consistent results.
In the second half of 1945, Thomas began reading for the BBC Radio programme, Book of Verse, broadcast weekly to the Far East. This provided Thomas with a regular income and brought him into contact with Louis MacNeice, a congenial drinking companion whose advice Thomas cherished. On 29 September 1946, the BBC began transmitting the Third Programme, a high-culture network which provided opportunities for Thomas. He appeared in the play Comus for the Third Programme, the day after the network launched, and his rich, sonorous voice led to character parts, including the lead in Aeschylus's Agamemnon and Satan in an adaptation of Paradise Lost. Thomas remained a popular guest on radio talk shows for the BBC, who regarded him as "useful should a younger generation poet be needed". He had an uneasy relationship with BBC management and a staff job was never an option, with drinking cited as the problem. Despite this, Thomas became a familiar radio voice and within Britain was "in every sense a celebrity". The publication of Deaths and Entrances in February 1946 was a major turning point for Thomas. Poet and critic Walter J. Turner commented in The Spectator, "This book alone, in my opinion, ranks him as a major poet".
Sources: en.wikipedia.org
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.
Peptidases degrade the compound within minutes in circulation. This short half-life is one reason nasal delivery is used, placing the substance close to the olfactory and trigeminal pathways.
No large multicenter trials have been published in English-language journals. The existing human evidence consists mainly of smaller studies conducted in Russia, which limits generalization.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.